



Symic to Present at the 23rd Annual BioCentury Future Leaders in the Biotech Industry Conference

SAN FRANCISCO, Mar. 1, 2016 – Symic, a clinical-stage biotherapeutics company developing multiple compounds that target and affect the extracellular matrix (ECM), today announced that Ken Horne, Chief Executive Officer, will present at the 23rd Annual BioCentury Future Leaders in the Biotech Industry Conference in New York.

Conference details are as follows:

Date: Friday, Mar. 11, 2016

Time: 11:00 a.m. EST

Location: Millennium Broadway Hotel & Conference Center, New York City

About Symic

Symic is a clinical-stage biotherapeutics company developing multiple compounds that target and affect the extracellular matrix (ECM), the non-cellular component of tissues that is critical for healthy tissue function. Components of the ECM, particularly proteoglycans, which are important structural and functional macromolecules native to the ECM, play a critical role in healing following injury and in chronic diseases. Symic's proprietary compounds function like proteoglycans, and have been designed to promote healing and repair in a variety of disease states. Symic's lead compound, SB-030, is currently under evaluation in the Phase 1/2 SHIELD clinical trial for vascular endothelial injury. In addition, Symic's osteoarthritis drug candidate, SB-061, is poised to enter the clinic in the next few months.

Symic is based in San Francisco. For additional information, please visit the company's website at <http://www.symic.bio> or follow us on Twitter at www.twitter.com/symicbio and LinkedIn at www.linkedin.com/company/symic-bio/.

###

Media Contacts

David Schull or Lena Evans
Russo Partners, LLC
(212) 845-4271
(212) 845-4262

david.schull@russopartnersllc.com

lana.evans@russopartnersllc.com